Multiple myeloma · 4 regimens
Cost vs Efficacy · 3 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
ITd Variant #01 | — | R 41 519 | 28d | 20.0 mo | — | 3 | R 115 868 PFS proxy | 1 |
Bortezomib monotherapy Variant #03 | — | R 6 762 | 21d | 33.6 mo | — | 8 | R 54 096 PFS proxy | 3 |
Melphalan monotherapy Variant #01 | — | R 73 | 42d | 50.0 mo | — | 18 | R 1 320 PFS proxy | 4 |
Observation Partial | — | — | — | 13.0 mo | — | — | — | 1 |
4 of 4 regimens shown